Casi Pharmaceuticals Stock Return On Equity
| CASI Stock | USD 1.20 0.03 2.44% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess CASI Pharmaceuticals' long-term financial health and intrinsic value.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CASI Pharmaceuticals Company Return On Equity Analysis
CASI Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current CASI Pharmaceuticals Return On Equity | -10.94 |
Most of CASI Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, CASI Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, CASI Pharmaceuticals has a Return On Equity of -10.945. This is 54.34% lower than that of the Biotechnology sector and 69.98% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
CASI Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CASI Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of CASI Pharmaceuticals could also be used in its relative valuation, which is a method of valuing CASI Pharmaceuticals by comparing valuation metrics of similar companies.CASI Pharmaceuticals is currently under evaluation in return on equity category among its peers.
CASI Fundamentals
| Return On Equity | -10.94 | |||
| Return On Asset | -0.62 | |||
| Profit Margin | (1.84) % | |||
| Operating Margin | (3.33) % | |||
| Current Valuation | 39.86 M | |||
| Shares Outstanding | 15.49 M | |||
| Shares Owned By Insiders | 43.78 % | |||
| Shares Owned By Institutions | 17.14 % | |||
| Number Of Shares Shorted | 136.98 K | |||
| Price To Earning | (16.46) X | |||
| Price To Book | 11.21 X | |||
| Price To Sales | 0.71 X | |||
| Revenue | 28.54 M | |||
| Gross Profit | 9.61 M | |||
| EBITDA | (34.87 M) | |||
| Net Income | (39.26 M) | |||
| Cash And Equivalents | 24.57 M | |||
| Cash Per Share | 1.81 X | |||
| Total Debt | 22.14 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 3.21 X | |||
| Book Value Per Share | (1.39) X | |||
| Cash Flow From Operations | (29.22 M) | |||
| Short Ratio | 0.77 X | |||
| Earnings Per Share | (3.02) X | |||
| Target Price | 4.0 | |||
| Number Of Employees | 233 | |||
| Beta | 0.82 | |||
| Market Capitalization | 19.06 M | |||
| Total Asset | 53.67 M | |||
| Retained Earnings | (700.08 M) | |||
| Working Capital | 3.12 M | |||
| Current Asset | 17.15 M | |||
| Current Liabilities | 3.51 M | |||
| Net Asset | 53.67 M |
About CASI Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CASI Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CASI Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CASI Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether CASI Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of CASI Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Casi Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Casi Pharmaceuticals Stock:Check out CASI Pharmaceuticals Piotroski F Score and CASI Pharmaceuticals Altman Z Score analysis. For more detail on how to invest in CASI Stock please use our How to Invest in CASI Pharmaceuticals guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CASI Pharmaceuticals. If investors know CASI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CASI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CASI Pharmaceuticals is measured differently than its book value, which is the value of CASI that is recorded on the company's balance sheet. Investors also form their own opinion of CASI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is CASI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CASI Pharmaceuticals' market value can be influenced by many factors that don't directly affect CASI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CASI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if CASI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CASI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.